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1. Introduction 
New infectious diseases emerge with a high regularity; it has recently been estimated that a 
novel infectious disease agent either emerges or re-emerges approximately every 8 months. 
This latter statistic is supported by the observation that there have been over 335 emerging 
infectious disease (EID) events between 1940 and 2004 (Jones et al., 2008). Of course, not all 
of these EID events represent a threat to human health, indeed many of these are infections 
of animals, although approximately 60% are also zoonotic infections (which by definition 
can be transmitted between animals and humans); another additional proportion also have 
the potential to cross the species barrier. Since 1970 there have been approximately 30 new 
species of pathogen emerge which cause human infection. Table 1 lists these pathogens 
(taken from World Health Organisation, 1999). 
 
Year Pathogen Year Pathogen
1972 Small Round Structured Viruses 1989 Hepatitis C virus
1973 Rotavirus 1990 Human herpesvirus-7
1975 Astrovirus 1990 Hepatitis E virus
1975 Parvovirus B-19 1991 Hepatitis F virus
1976 Crytosporidium parvum 1992 Vibrio cholerae 0139:H7
1977 Ebola virus 1992 Bartonella henselae
1977 Legionella pneumophila 1993 Sin Nombre virus
1977 Hantaan virus 1993 Hepatitis G virus
1977 Cambylobacter jejuni 1994 Sabia virus
1980 HTLV-1 1994 Human herpesvirus-8
1981 Toxigenic Staphylococcus aureus 1995 Hendra virus
1982 HTLV-II 1996 Prion (BSE/vCJD)
1982 Borrelia burgdorferii 1997 Influenza A virus (H5N1)
1983 E.coli 0157:H7 1997 Transfusion-transmitted virus 
1983 HIV 1997 Enterovirus 71
1983 Helicobacter pylori 1998 Nipah virus
1988 Human herpesvirus-6 1999 Influenza A virus (Hong Kong ‘flu) 
1989 Ehrlichia spp. 1999 West Nile virus
Table 1. Emerging Infectious Disease Pathogens, 1972-1999. 
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An emerging infectious disease may be defined as one that has appeared in a population for 
the first time, or that may have existed previously but is rapidly increasing in incidence or 
geographic range (World Health Organisation [WHO]). This definition is quite generic and 
many consider EID’s as those which are either genuinely novel infectious disease pathogens 
(examples include the SARS coronavirus which emerged in 2003) or those where there has 
been a paradigm shift in their genotype or phenotype such that it poses a new threat to 
health (examples include the appearance of multi-drug resistant Mycobacterium tuberculosis 
and other bacterial pathogens). These latter pathogens are frequently referred to as re-
emerging infectious diseases, to discriminate them from completely novel disease agents. 
Because of the apparent rise in the incidence of EIDs during the 1980’s and 90’s (HIV/AIDS, 
vCJD etc.), factors involved in the process of emergence were analysed by a number of 
workers. One such study (Taylor et al., 2001), concluded that although over half of EIDs 
were zoonotic in origin, the route of transmission had no effect on the likelihood of 
emergence, rather it was the taxonomy of the organism that was the root cause. They 
concluded that viruses and bacteria were of much higher likelihood of emergence, whereas 
parasites such as Helminths, were very unlikely to ever emerge.  
Despite the advances in medical science, infectious diseases still constitute a threat to human 
survival, health and well-being and have done since human life began. Immediately 
following the discovery of penicillin, there was a mood of optimism that felt that the 
conquest of infectious diseases was a war that had been won; rather it seems it was merely 
the first skirmish in a very long-lasting battle. In the first decade of the 21st century, we 
know that infectious diseases represent a major global threat, accounting for some 41% of 
the global disease burden and in the UK alone, infectious diseases now account for 
approximately 70,000 deaths per annum and 40% of the population in the country consult a 
medical practitioner each year because of infection (Donaldson, 2001). It is clear, therefore, 
that infectious diseases remain a major global threat and that the burden of disease with an 
infectious aetiology is very high. There are a large number of interventions that can be 
applied to the control of infectious disease and for health protection. Interventions include 
simple public health control measures (hand-washing, quarantine, supply of clean water 
etc.), diagnostic tests, therapeutic treatments and vaccines. These different aspects will be 
discussed in greater depth in the following sections. 
2. Vaccination 
Vaccination is the process by which the adaptive immune system is stimulated to produce a 
deliberate response. Typically, vaccines comprise an antigenic component (or components) 
which are administered by a variety of routes and mimic the infection against which 
protection is sought. Modern vaccination was probably first described by Edward Jenner 
(there are reports that a similar approach had been used some years earlier) in 1796; indeed 
it was Jenner who coined the phrase vaccination. The term is derived from the Latin word 
vacca meaning “cow”, so derived since the first “vaccination” used material from cowpox 
viral lesions on a milk-maids hands as protection against Smallpox infection (reviewed in 
Lombard et al., 2007). Strictly, vaccination may be considered to be the process of 
introducing a foreign antigen into the body for the purpose of protection against infectious 
disease, whereas, immunisation is the process by which a vaccine induces an immune 
response against a foreign antigen – a subtle difference in meaning, although in practice the 
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two terms are often used interchangeably. From these early beginnings, there are 26 
currently licensed vaccines widely available and administered as components of vaccination 
programmes. These 26 vaccines are shown in Table 2 below. 
 
Vaccine Vaccine 
Anthrax Pertussis 
Cervical cancer (papilloma virus) Pneumococcal infection 
Chicken pox virus Poliomyelitis 
Cholera Rabies 
Diphtheria Rotavirus 
Group A & C Meningococcal infections Rubella 
Hib infection Shingles 
Hepatitis A Smallpox 
Hepatitis B Tetanus 
Japanese encephalitis Tuberculosis 
Influenza Typhoid Fever 
Measles Varicella 
Mumps Yellow Fever 
Table 2. Licensed Vaccines Currently Available for Use. 
The table above illustrates that there are available vaccines for many of the “common” 
infectious diseases, yet despite this availability, there still exists a considerable disease 
burden for many of the diseases shown in Table 2. One might reasonably question why this 
is so, and the answer is multi-fold. Firstly the aspect of vaccine efficacy needs to be 
considered; the availability of a licensed vaccine does not, of course, indicate that use will 
result in 100% protection of the recipient. Due to the very different immune profiles 
observed within the human population, there will be a response curve which at one end 
results in next to no (or at least very low) levels of protection, whereas at the other end of 
the scale, recipients will show good protection. Taken on a population level, this means that 
there will always be a proportion of the population which are unprotected and thus the 
disease is still able to circulate. The above reasoning also assumes that take-up (and indeed 
availability) of any vaccine is 100% within a population; it is not due both to the cost 
involved in vaccinating entire populations and the choice which some make not to receive 
vaccination when offered. This latter point is very well illustrated by the recent issues 
surrounding the MMR (Measles, Mumps & Rubella) tri-valent vaccine within the UK. 
Adverse scientific publications (for an update on the current scientific evidence and lack of 
any link between these events see DeStefano & Williams, 2004), indicating a link between 
receipt of the vaccine and autism in children has meant that many parents decided not to 
allow their children to receive the vaccine and the UK now has a considerable measles 
outbreak due to much higher levels of susceptibility within the population (see ECDC 
measles Surveillance Report, 2011). It is of note, though, that the risk of real adverse events 
with the MMR vaccine are very low; the risk of brain damage due to receipt of the vaccine is 
calculated to be approximately 1/100,000 (this is due to the measles component of the 
vaccine), whereas the risk of brain damage if a child catches measles is approximately 
1/1000, a figure which is considerably higher. 
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2.1 Types of vaccine 
There are basically three ways of making vaccines against infectious diseases, all rely on a 
level of knowledge about the pathogenesis of the disease and ideally about the virulence 
factors which the pathogen employs. That vaccination is an effective method to protect the 
health of a population is well known and documented; the figure below illustrates the 
reduction in numbers of ill and in numbers of deaths for a fictitious respiratory disease, 
spreading with a population of approximately 60 million people (Fig. 1). A large number of 
assumptions have been made in running this very simple Susceptible, Infected, Recovered 
(SIR) model, one of which was that a new vaccine had to be developed and that the time 
taken to both produce a crude, whole-cell vaccine, plus manufacture enough to be used 
widely, resulted in an approximately 50% reduction in the overall numbers of fatalities (C. 
Norris & N J Silman, Unpublished). Of course, modelling the same disease, but making the 
assumption that a vaccine already exists can reduce the impact of the disease even more 
than that shown in Fig.1.  
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Fig. 1. SIR Model of the Impact of Vaccine Introduction on the Course of Infectious Disease. 
Key: ____ Susceptible population; _ _ _ Infected population; ___ Infected population after 
vaccine introduced; _ _ _ Fatalities if vaccine not used; ______ Fatalities when vaccine used; 
___ Numbers Recovered 
This figure is shown merely to illustrate the point that development of a new vaccine in the 
event of an emerging disease can have a very profound effect on the outcome of the disease 
(this point was well made during the recent H1N1 influenza pandemic). The illustration also 
includes an element of diagnostic roll-out, where we made the assumption that in the early 
stages of a newly emerged pathogen, simple public health control measures would be 
invoked to control person to person transmission and that these measures would be 
supported by a diagnostic test. 
The three different approaches to vaccine development will be discussed in greater detail in 
the sections which follow, and their potential for use in producing vaccines against rapidly 
emerging pathogens will be discussed further. 
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2.1.1 Whole-cell vaccines 
The simplest vaccines comprise growing up the pathogen and inactivating a crude, 
unfractionated preparation. This is an approach which has been used for a considerable 
length of time and vaccines made using this relatively simple rationale are still widely used. 
Examples taken from table 2 include Anthrax, Japanese encephalitis, influenza, yellow fever 
and typhoid fever; the reader will note that both bacterial and viral vaccines are made using 
the same approach and both types can show good efficacy in use. There are, of course, a 
number of examples where such an approach is not successful; examples here include 
vaccines that were produced against Cholera, Plague, meningitis and Smallpox. These 
vaccines failed because of a paucity of understanding of the mechanisms of virulence (e.g. 
the major virulence factor for Cholera is a toxin and thus a crude whole-cell preparation 
would not contain this secreted component). However, it is still considered that this method 
of rapidly producing a vaccine could be used in the event of a newly emerging infectious 
disease that had a high mortality rate and was highly transmissible within the population. 
Although there are examples of vaccines for both bacteria and viruses produced by this 
method, it is generally considered that the approach is probably more suited to production 
of viral vaccines due to their lower complexity. Probably the most commonly used vaccine 
of this type which is still produced and updated year on year is the split virion influenza 
vaccine that is produced seasonally. This vaccine comprises an unpurified preparation of 
virus typically grown in egg-culture (although there are notable examples of cell-culture 
grown influenza virus vaccines which are licensed for use or in clinical trial) and 
inactivated. The rationale is that the major antigenic components of the influenza virus are 
the haemagglutinin and neuraminidase, both of which are surface proteins against which 
considerable immune responses are mounted. Interestingly, despite the longevity of use of 
this vaccine and the considerable number of clinical trials and research work that has been 
conducted, the correlates of protection for influenza are still unknown (Montomoli et al., 
2011). 
Looking at the list of recently emerged pathogens shown in Table 1, it is interesting to note 
that this approach has been used to develop vaccine candidates for a number of the 
pathogens. The most notable example is HIV/AIDS, for which there is still no effective 
vaccine and that an inactivated viral preparation did not exhibit high protective efficacy. 
Thus, for this method of vaccine development to be of value for an emergent pathogen a 
number of criteria need to be fulfilled, some of which will not be obvious when the disease 
first emerges. Firstly, the disease needs to have a high mortality rate, such that use of a 
vaccine is absolutely required. Secondly, it must be highly transmissible, since an infection 
with a low rate of transmission (R0) can be controlled by other public health measures, a 
good example of such a pathogen was the SARS coronavirus, which was transmissible but 
had a relatively low R0 and thus was adequately controlled by quarantine. Thirdly, natural 
infection should induce a protective immunity, otherwise an inactivated preparation is 
unlikely to induce immunity if the natural infection is incapable of so doing. This last 
consideration is very unlikely to be understood at the point when the pathogen emerges and 
will only be fully understood after a considerable length of time, most probably once an 
epidemic or pandemic situation has passed. The speed that a vaccine must be deployed is 
illustrated in Fig.2, which shows the effect on the numbers of infectious people within a 
population as the reproduction rate of the infectious disease pathogen is varied.  
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Fig. 2. Effect of Varying R0 on the Number of Infectious People within a Population. 
This figure illustrates a modest range of R0 values between 1.2 and 1.6, the point to note is 
that even with small variations in the R0 value, large differences in the numbers of infected 
people are observed and the time that maximum numbers of people are infected varies 
between approximately 130 and 240 days. This should be compared with the reproduction 
rate of typical influenza viruses which may be up to R0 = 3 (that is, 3 uninfected people are 
infected by each infectious member of the population). The lower values used in this 
illustration were seen with the SARS coronavirus and perhaps illustrate why a vaccine was 
not developed against this pathogen during the epidemic phase. 
2.1.2 Attenuated vaccines 
Another approach to the rational design of vaccines for existing or emerging pathogens is 
the attenuation of virulent strains. Here, a strain is used which is not able to produce 
fulminant infection as a result of its’ attenuation. In contrast to the inactivated vaccines 
described in section 2.1.1, these vaccines comprise live micro-organisms. Historically, 
attenuated strains were first obtained by serendipity often following prolonged sub-culture 
or passage (for example see Barrett et al., 1990). Good examples of this occurrence are the 
Yellow fever 17D strain which was naturally attenuated by repeated passage and has been 
used as a vaccine against this disease since the 1950’s. Interestingly, the mechanism of 
attenuation is still not known, although the vaccine has a long history of safe use, except in 
those members of the population with an egg allergy (the virus is propagated in egg 
culture). Another well-known example of an attenuated vaccine strain is the Polio virus 
vaccine, of which there are two vaccines in use. The first, the Salk vaccine is an inactivated 
viral preparation whilst the second, called the Sabin strain is an attenuated Polio virus (see 
Pearce, 2004). The Sabin vaccine was trialled between 1957 and 1962, when it was licensed 
for widespread use. The vaccine is taken orally and was attenuated by repeated passage in 
the brains of mice. By the seventh passage the virus was found to be no longer capable of 
infecting mice via the neurological route. A further 2 to 3 passages through rats confirmed 
the attenuation and the strain was considered safe for human inoculation. The development 
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of polio vaccines in the 1950’s was a response to the large burden of disease caused by this 
virus and delivery of the Salk and Sabin vaccines constitutes the first mass-immunisation 
programmes. At the current date, Polio is still yet to be eradicated, despite efforts which 
began in 1988 between the WHO, UNICEF and the Rotary Foundation, however the hope is 
that this virus will soon be committed to history. 
As the above example illustrates, the process of attenuation is not one which can be 
undertaken rapidly. There is no rational way of determining whether a strain may be 
attenuated by simple repeated passage or not and therefore the utility of such an approach 
is of limited value in responding to emergence of new infectious diseases. There are, of 
course, alternative ways of attenuating pathogenic strains of microorganism. For example, 
in the time between isolation of the Sabin strain and the present day, the mutations which 
are responsible for this strains lack of neuro-infectivity have been mapped to the internal 
ribosome entry site (IRES) of the virus in the currently used strain, a derivative of the 
original Sabin isolate. Extensive characterisation of the series of viruses that have been used 
as live-attenuated Polio vaccines has indicated that there are fifty-seven nucleotide 
substitutions which distinguish the attenuated Sabin 1 strain from its virulent parent (the 
Mahoney serotype), with a two further nucleotide substitutions between the Sabin 2 and 
parent strain, and ten more substitutions are involved in further attenuating the Sabin 3 
strain (Kew et al., 2005). 
An alternative to repeated passage is the rational deletion of one or more genes from the 
genome of the organism. This approach requires in-depth knowledge of the virulence or 
pathogenicity factors which the infectious micro-organism uses to achieve infection in the 
human host. There are a number of examples where this approach has been successfully 
used. In view of the subject within this chapter to look at prospects for emerging infectious 
diseases, the live attenuated influenza vaccine (LAIV) will be used as a discussion example 
to illustrate this approach. There is currently only one licensed influenza vaccine based 
upon this LAIV technology, although, like other influenza vaccines, the virus backbone is 
used to construct vaccines against currently circulating strains by recombination with the 
genomic segments encoding the haemagglutinin and neuraminidase genes from the 
currently circulating strains. The LAIV is licensed in the USA by FDA and sold under the 
trade name of FluMist™. The backbone strain used for this vaccine is a cold-adapted strain 
which is attenuated since it is not able to complete the cycle of replication at normal human 
body temperatures. The relatively small genome of the influenza virus has been completely 
sequenced from this strain and many nucleotide substitutions have been made to ensure 
that the strain cannot revert and also to improve its growth properties in cell, rather than 
egg culture as this is a more scalable technology for rapid vaccine manufacture than is egg 
culture.  
A similar approach may be envisioned for viral groups such as the Flaviviruses. This is an 
important group of viruses, whose members have been responsible for several infectious 
disease outbreaks during the last two decades. Their members include Yellow fever virus, 
West Nile virus and Dengue virus and they are viruses with segmented RNA genomes. One 
of the key factors in the emergence of new pathogens is the presence of an RNA genome as 
this allows rapid recombination, mutation and hence evolution and adaptation. This group 
is therefore of great importance when horizon scanning for the next emergent viral disease 
and only one flavivirus already has a licensed vaccine (Yellow fever). There are vaccines 
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against Dengue virus in clinical trial, since this is a disease with a worldwide distribution 
and serious complications can be observed if re-infection with a different serotype occurs 
(Dengue haemorrhagic fever). West Nile virus is a classic example of an emergent viral 
infection; it arose in the West Nile delta in North Africa and was transported by cervid birds 
into North America where, as it is a mosquito vector-transmitted disease, it has caused 
seasonal outbreaks in every subsequent year (see Campbell et al., 2002). Chikungunya virus 
has similarly spread across the Indian Ocean and has also been imported into Europe where 
it caused a limited outbreak in Italy during 2009 (Beltrame et al., 2007). It is likely that 
infection with one flavivirus induces an immunity against some other viruses within the 
group, based on the observation that antibodies against many of these viruses cross-react 
with flaviviral antigens in ELISA assays and thus make clinical infection with a particular 
virus impossible to diagnose by serology alone. By comparing different flaviviruses with the 
Yellow fever 17D vaccine, it should be possible to produce vaccines against this range of 
viruses by using the same approach to attenuate different viruses. What is unknown, once 
again, are the correlates of immunity for not only Yellow fever infection but for any of the 
other flavivirus infections. Care will also be needed to avoid any complications by priming 
the immune system as are seen in Dengue virus infection. As a method of rapidly producing 
a vaccine strain, attenuation by repeated passage is not useful due to the extensive length of 
time that it may take to produce an attenuated virus and the additional time required to 
demonstrate irreversible attenuation. 
2.1.3 Sub-unit vaccines 
Probably the most rapid way to make a vaccine against a newly emerging pathogen is to use 
a recombinant technology approach and identify a single immunogenic antigen, clone out 
and express the gene encoding that particular antigen. A common theme that we have 
observed whilst discussing vaccinology, is that rational vaccine design has an absolute 
requirement for good understanding of both the factors which affect pathogen virulence as 
well as those which contribute to immunity in the host. Although this has been discussed 
previously, it bears repeating that in the event of a newly emerging pathogen, these data 
will not be available and that the second best approach is to fall back to an inactivated whole 
pathogen preparation. Assuming, however, that we are aiming to develop a vaccine against 
a pathogen which is similar to one about which we have considerable knowledge, then a 
rational sub-unit approach is likely to be used. Once again the caveat is that a single sub-
unit(s) may not induce complete protective immunity, as there may well be multiple 
components involved in protection following natural infection. There are numerous 
examples where single sub-unit vaccine candidates fail to provide complete or even any 
protection, a good illustration of this observation is the lack of complete protection afforded 
by single sub-unit vaccines in HIV infection (inactivated virus also fails to induce protection 
though). 
Yersinia pestis, the bacterial causative agent of plague, is a re-emergent infection as it has 
caused recent outbreaks in geographical areas that have previously not experienced 
infections caused by this organism. Fig. 3 below illustrates that although there are a large 
number of surface antigens, against which an immune response is induced (as determined 
by the presence of human antibody response), only two are associated with protective 
immunity, these are the F1 and V antigens and both are virulence factors encoded by 
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transferrable plasmids. A vaccine containing the F1 and V-antigens is being developed, 
although because of the low prevalence of disease, it is unlikely to be widely used. As an 
exemplar of the approach that can be taken with emerging and re-emerging diseases, it 
illustrates perfectly the requirement for a thorough understanding of the pathogenesis of the 
organisms as well as understanding the host immune response. 
 
Fig. 3. Identification of Protective Antigens in Yersinia pestis. 
3. Therapeutic interventions 
There are a great number of therapeutic interventions that can be applied to the control of 
infectious diseases. The key type of interventions are discussed in greater detail below, and 
as a general trend, we have observed a move towards more targeted approaches to design of 
therapeutic compounds. During the last 30 years, the period under discussion when 
considering emerging infectious diseases, there has been a marked change in the scientific 
approaches to discovery of therapeutic molecules. There were a great many researchers 
using natural product libraries during the 1970’s and 80’s to discover compounds with 
activity against a wide range of biological activities; of relevance to infectious diseases are 
those which exhibited antimicrobial activity. A consequence of these high-throughput 
screening programmes was that several new classes of antibiotic were discovered during 
this time, but subsequently there have been very few new discoveries and there is now a 
real shortage of new antimicrobial compound groups to counteract the rise of antimicrobial 
resistance. Future research to meet clinical unmet needs, must incorporate the rational 
design and discovery of new ways of combating antimicrobial resistance, be it new 
antibiotics or other therapeutic approaches. 
3.1 Antimicrobial compounds 
The majority of currently licensed antibiotics were discovered between 40 and 60 years ago 
and modern drugs are mostly derivatives of existing classes of drug. Despite the increased 
need to treat expanding populations against micro-organisms exhibiting increasing levels of 
resistance, there has been a reduction in the effort by the major pharmaceutical companies to 
discover new antibiotics (Marinelli, 2009). There have been a number of high, but unrealised 
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expectations driven by high-throughput screening, combinatorial chemistry and microbial 
genome sequencing that have failed to deliver the new compounds required. It is interesting 
to note that during the “Golden Age” of antibiotic discovery (1940-1960) approximately 
12,000 compounds were screened and resulted in 160 licensed products (0.01%). This 
statistic played a major part in the evolution of antibiotics where research effort was 
directed towards the improvement of existing chemotypes (increased potency, stability and 
pharmokinetics, reduced side-effects) rather than discovery of novel compound classes. 
Those that did continue to invest research funds into discovery rather than improvement 
were rewarded by the discovery of some new chemotypes such as thienamycin, daptomycin 
and echinocandins. One of the main confounders to the discovery of new compounds was 
the high rate of re-isolation of existing compounds, requiring a different approach to 
screening assays from the traditionally used inhibition of bacterial growth that has been 
used since Alexander Fleming discovered Penicillin in 1928. This need has led to the 
introduction of functional, cell-free assays, but this has not resulted in the desired increase 
in discovery of novel compounds. Moreover, the availability of whole genome sequence 
data for a wide range of pathogenic bacteria and viruses similarly has not resulted in 
discovery of novel chemotypes, despite high investment by the pharmaceutical companies. 
There are, however, several prospects for the discovery of new classes of chemotype. The 
first of these is to harness the wealth of structural data that are now available, but this 
approach requires an in-depth knowledge of the biology of the target micro-organism. There 
are a number of documented examples of this approach being coupled with virtual high-
throughput screening (VHTS) against virtual compound libraries. One example is that 
described by Reddy et al. (2006) for the rational discovery of small molecule inhibitors of 
prion protein, a key emergent disease. Here a virtual compound library was screened for 
molecules that would theoretically bind and inhibit prion protein from entering cells. A 
similar approach has been taken to the design of inhibitors of the Anthrax toxin cell-binding 
component (protective antigen; PA) which combines with two further toxin components to 
exert the toxic effects, which typically result in death of the animal or human host. The 
protein crystallography data were used for the PA molecule and the cell-receptor binding 
site was identified from published research (Bradley et al., 2001). This crystal structure was 
screened using VHTS and small-molecule inhibitors of this binding reaction were identified 
and then synthesised and screened in vitro using functional assays for one of the two 
Anthrax toxins (lethal toxin, a combination of PA and lethal factor). Many of the molecules 
screened using this approach were subsequently found to have significant activity in the in 
vitro assays; approximately 3% of the compounds screened were found to possess activity, 
compared with the 0.01% that are typically obtained by high-throughput screening of 
compound libraries (B. Chen, personal communication). This approach clearly holds much 
promise for the rational design of novel chemotypes of antimicrobial compound and the 
approach works irrespective of whether the pathogen is a virus or bacteria. This is therefore, 
an attractive approach for the development of targeted inhibitors of a range of processes 
involved in the pathogenesis of disease. The main caveat, though, is that a thorough 
understanding of the virulence factors and pathogenesis of the disease are needed, along 
with suitable structural data to enable this approach to be used to combat emerging 
diseases. Clearly, when a pathogen first emerges, it is completely uncharacterised and such 
a directed approach is not possible. 
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Other approaches to the discovery of new chemotypes are the screening of compound 
libraries derived from different sources. This approach somewhat mimics the approach used 
during the “Golden Age”, in that compound libraries are screened using high-throughput 
methods and inhibition of microbial growth at this stage is a precursor to further 
characterisation. The libraries from which most antibiotics were derived are soil organisms, 
but there are also untapped resources in the oceans, where there is a large number and 
range of micro-organisms and from plant extracts where a number of compounds have 
already been shown to possess antibacterial and/or antiviral activity. Examples are the 
extracts from the garlic and clove plants (Arora & Kaur, 1999).  A range of spice plants were 
screened for activity and only these two extracts exhibited antimicrobial activity, however, 
they were active against a range of Gram positive and Gram negative bacteria and yeasts.  
As an adjunct to antimicrobial compounds, we should also consider those compounds 
which modify activity of existing drugs. Such examples include ß-lactamase inhibitors such 
as clavulanic acid (used as a proprietary preparation in conjunction with amoxicillin and 
other ß-lactam antibiotics) and efflux inhibitors which maintain an elevated drug 
concentration within cells and hence improve antimicrobial efficacy. 
3.2 Therapeutic antibodies 
An alternative therapeutic approach to emerging infectious diseases is the use of antibodies 
to treat disease. This is a concept which has existed for a considerable time, however, only 
relatively recently have therapeutic antibodies really been used against infectious diseases. 
As of 2006, there were 20 therapeutic antibodies approved as therapeutics by the FDA (Das, 
2006), but they offer considerable potential for the rapid treatment of emerging infectious 
diseases. One may question why this should be; the answer is straightforward, since 
protection from infection by pathogenic micro-organisms may be either active, and induced 
by immunization using prophylactic vaccines (see section 2.1), or passive. One of the issues 
discussed in section 2 was that prophylactic vaccines take a considerable time to make and 
formulate and these can be too slow for a pathogen with a high rate of reproduction (R0) in a 
susceptible population. Passive immunity, where specific antibodies are administered, is a 
viable alternative here and also for the treatment of diseases where antimicrobial therapy 
may exacerbate the disease symptoms and also result in higher transmissibility (e.g. 
ulcerative colitis caused by Clostridium difficile infection and toxin). Many advances have 
been seen over the past decade which has allowed improved antibody engineering 
technologies along with improvements in safety and efficacy. These developments, along 
with a greater understanding of the immunomodulatory properties of antibodies, have 
paved the way for the next generation of new and improved antibody-based drugs for the 
treatment of human diseases. One major factor that makes this an attractive technology is 
that antibody “factories” can be rapidly turned around to produce a stock of antibodies for 
therapeutic use. This approach was recently described by Rogers et al. (2008) where they 
developed a panel of neutralising antibodies against the SARS coronavirus, a recently 
emerged pathogen, using a novel DNA display method. They describe their approach which 
involved panning the library using whole SARS virus rather than just the spike protein 
(which had been used by others, being a primary virulence factor for cell binding and entry). 
Other therapeutic antibody approaches in development include those to treat toxigenic 
effects following bacterial infection (Clostridium difficile, verotoxigenic E.coli, Anthrax toxin). 
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The use of therapeutic antibodies certainly holds much promise for the treatment of 
infectious diseases and is particularly attractive due to the rapidity that recombinant 
antibodies may be selected, produced and manufactured at scale. 
3.3 Other therapeutics 
There are a considerable number of other therapeutic approaches in development or at the 
research stage, far too many to comprehensively review here. Instead, we will concentrate 
on some of the key areas where there are noteworthy developments.  
3.3.1 Therapeutic vaccines 
Firstly, we will consider therapeutic vaccines. In section 2 previously, we have considered 
the use of vaccines for induction of prophylactic immunity. There is an alternative use of 
some vaccines, however, and this is for prophylaxis following exposure to an infectious 
disease micro-organism. A good example is the AIDS virus, HIV, which emerged in 1983 
and for which, despite many attempts, there is no prophylactic vaccine. The Norwegian 
biotech company, Bionor Pharma recently released results from a study of its therapeutic 
HIV vaccine, Vacc-4x. There are recent data showing that the vaccine lowered patients' viral 
loads and negated the need for antiretroviral therapy (Fierce Vaccines, 2011). 
3.3.2 Phage therapy 
Phage therapy entails the use of bacteriophage viruses that infect bacteria for the treatment 
of bacterial infections. Phages are ubiquitously found in bacterial populations and control 
the growth of bacteria in many environments, including in the intestine, the oceans, and the 
soil. Phage therapy was in used in the 1920s and 1930s in the USA, Western & Eastern 
Europe, however, success rates of this therapy have never been firmly established, because 
only a limited number of clinical trials testing the efficacy of phage therapy have ever been 
conducted. These studies were performed mainly in the former Soviet Union. The 
development of antibacterial-resistant bacteria has once again sparked renewed interest in 
phage therapy with several companies, universities and foundations across the world now 
focusing on phage therapeutics. One of the main difficulties is that of delivery of the phage 
to the site of infection, making them potentially more suitable for treatment of respiratory or 
skin diseases than for deep-seated infections. There is also the safety concern about giving 
live viruses to human subjects.  
3.3.3 Bacteriocins 
Bacteriocins are peptides that can potentially be more readily engineered than small 
combinatorial chemistry generated molecules and are potential alternatives to conventional 
antibacterial compounds. Different classes of bacteriocins have different potential as 
therapeutic agents. Small-molecule bacteriocins (e.g. microcins and lantibiotics) are similar 
to the classic broad-spectrum antibiotics whereas colicin-like bacteriocins possess a much 
narrower activity spectrum, and require pathogen identification (and susceptibility testing) 
prior to therapy. Limitations of large-molecule antibacterials include reduced transport 
across membranes and within the human body. For this reason, they are usually used 
topically or gastrointestinally.  
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3.3.4 Chelation 
A novel approach relies on the removal of essential nutrients for bacterial growth within the 
host by chelation. These compounds are not suitable for use alone, but may have utility in 
combination with conventional antibacterial compounds. A similar approach forms the 
basis of a treatment for lymphoblastic leukaemia, where bacterially-derived L-asparaginase 
is used as a therapeutic to remove L-asparagine, an essential amino acid for leukaemia cells 
to grow and divide, from the circulating blood stream and hence effectively “starving” the 
cancer cells. 
3.3.5 Probiotics 
Probiotics consist of live cultures of bacteria, which may become established as competing 
commensal organisms and thus inhibit or interfere with colonization by microbial 
pathogens. This approach has been used to reduce nasal carriage with Methicillin-resistant 
Staphylococcus aureus (MRSA) by replacement therapy using a skin commensal 
Corynebacterium sp. (Uehara et al. 2000). 
4. Diagnostic tests 
Diagnostic testing is not a therapeutic intervention, of course, but like other public health 
control measures, this chapter would be incomplete without mention of its use. In the early 
stages of an outbreak caused by any infectious disease pathogen, the public health control 
measures are inevitably supported by diagnostic testing. When a new disease emerges, the 
only factor that can be used for diagnosis is the clinical presentation. This is frequently 
compounded by the observation that many diseases present at the early stage with non-
specific symptoms that are common with many less severe diseases. For example, the early 
symptoms of the SARS virus are very similar to many other respiratory infections caused by 
a range of viral pathogens, most of which do not require any intervention. Thus the power 
and value of a good diagnostic is in the differentiation of a pathogen causing severe 
infection from seasonally circulating infections of much lower consequence. Recently the 
Health Protection Agency undertook a study to model the value of rapid diagnostics 
development in the control of an outbreak caused by an emerging infectious disease (C. 
Noris & N. J. Silman, unpublished). The conclusion was that the diagnostic was of value 
only early in an outbreak when differential diagnosis was used to drive a policy of 
“containment” of the disease, that is, preventing onward transmission by preventing non-
infected persons coming into contact with those who were infectious. Of course, quarantine 
cannot be enforced, but it was an effective tool used in controlling the spread of the H1N1 
“swine” influenza pandemic during 2009. At the stage of the outbreak where containment is 
no longer possible, i.e. there are sufficiently high numbers of cases, then laboratory 
diagnosis ceases to have any real value in the CONTROL of the pandemic. That is not to say 
that it is of no value at all though. 
5. Public health control measures 
Although this chapter is focussing on the different therapeutic interventions that may be 
used to tackle the problems of emerging infectious diseases, it would be incomplete without 
mention of non-therapeutic means of controlling spread of infectious disease. In the initial 
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stages of responding to an emergent infectious disease, the only tools available to limit 
spread of the disease and prevent nosocomial infection of clinical staff are non-therapeutic 
public health interventions. Perhaps the earliest described successful approach was in 1854 
when John Snow removed the handle from a water pump in Broad Street, Soho, London. 
Before the discovery of pathogenic micro-organisms, Snow, a physician, was sceptical about 
the “miasma” theories that surrounded what we know to be infectious disease outbreaks. 
Miasma theory suggested that the cause of disease was a form of pollution or bad air. Snow 
carefully pieced together the evidence surrounding the distribution of the Cholera cases in 
the Soho area of London and concluded that the water pump in Broad Street was the 
common denominator; he removed the pump handle to prevent people from drawing and 
hence consuming water contaminated by Vibrio cholerae and very effectively curtailed the 
outbreak. 
The same general, non-therapeutic approach may be taken with newly emerging diseases. 
For example, many of the diseases that have emerged in the last 30 years have an insect 
vector involved in the dissemination of the infectious disease pathogen (Jones et al., 2008). 
The most effective intervention for vector-borne diseases is the eradication or reduction in 
the numbers of the insect vector using pesticides, rather than prophylaxis (not generally 
available) or therapeutics (Rose, 2001). Another recent example is the reduction in the 
numbers of cases of hospital acquired infection (HCAI). A contribution to this reduction is 
the reminder that good hand hygiene is vital and re-education of medical and nursing staff 
in the UK on good hand-washing practice, as well as the introduction of hand sanitizer gels 
(Grayson et al., 2009). Thus these important interventions, although mostly quite simple can 
have very pronounced outcomes in the control of infectious diseases. 
6. Conclusion 
There are a number of therapeutic interventions that can be used to combat emerging 
infectious diseases. When a new pathogen emerges and subsequently causes a widespread 
outbreak, the interventions that can be applied differ during the course of the outbreak. At 
the early stage, recognition of the disease is heavily reliant upon clinical case definition, as 
was used in differentiating the new variant H1N1 influenza virus in 2009, prior to the 
development of a molecular diagnostic assay. We have seen that the development of a 
diagnostic assay is used in support of clinical case definition. The most effective 
interventions are therapeutic or prophylactic ones, however, since they are able to either 
treat those infected or protect onward spread by inducing herd immunity within a 
population. The downside of a therapeutic approach against a newly emerging disease is 
the length of time that is required to develop an effective vaccine or therapeutic against any 
specific pathogen. Here we require more generic, broad-spectrum interventions such as 
antimicrobials. What is evident is that more investment in R&D to discover new therapeutic 
molecules that can be used against newly emerging pathogens. Currently we are relatively 
well-served by the availability of broad-spectrum antibiotics, but increasingly widespread 
multi-drug resistance is a major problem and new chemotypes are urgently required. 
Perhaps the greatest hope is available by using recombinant antibody technology, where 
using the high-throughput genome sequencing approaches now available, we can rapidly 
sequence newly emerged pathogens, clone out and express surface antigens for rapid 
development of therapeutic antibody preparations. Many countries have invested heavily in 
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infrastructure to build rapid vaccine facilities that can be turned around quickly in the event 
of the emergence of a new highly infectious pathogen and these sorts of adaptable facilities 
are of potentially great value in combating emerging infectious diseases. 
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